XtalPi Launches epiXora™, a Life Science-Specific AI Agent Empowering Trusted Decision-Making and Advancing Multi-Agent R&D Integration

July 8, 2026—XtalPi (2228.HK）Announced today, its solutions for life sciences and pharmaceutical R&D scenariosThe professional-grade AI research agent epiXora™ has been fully upgraded and launched, with registration now open for trial use.As a key extension of XtalPi’s “AI + Robotics + Multi-Agent” technology framework at the front end of decision-making, epiXora™ deeply integrates authoritative professional databases and R&D logic into workflows, providing credible, traceable, and reusable high-efficiency decision support for core scenarios such as target selection, pipeline evaluation, and external collaboration assessment. With the continuous improvement of the company’s multi-agent matrix,XtalPi is continuously deploying its proprietary scientific AI agents（Scientific Agent）Deploy to more research scenarios, building a digital intelligent hub for the industry to address complex innovation challenges.

In recent years, general-purpose AI tools have significantly improved the efficiency of information retrieval. However, in highly complex specialized fields such as life sciences, they often struggle with poor adaptability. In real-world scenarios like target assessment or R&D project initiation, general-purpose AI frequently suffers from insufficient coverage of professional data, a disconnect between analytical logic and decision-making pathways, and a lack of rigorous chains of evidence. These issues create an insurmountable "trust gap," preventing research findings from being directly adopted as the basis for decision-making. There is an urgent industry need to upgrade from "general information retrieval" to specialized Agentic AI. epiXora™ is designed precisely to address this industrial demand. It not only possesses the speed and breadth of general-purpose AI in processing vast amounts of information but also comprehends the highly rigorous decision-making logic inherent in biopharmaceutical contexts. By directly addressing the industry's core demands for certainty and credibility in conclusions, epiXora™ elevates AI-driven research from simple information summarization to a reliable "decision-support engine."

To truly liberate scientists from the tedious and inefficient processes of information collection and cross-validation using AI,epiXora™ reconstructs the digital foundation of biopharmaceutical research through massive professional data, a logical framework closely aligned with real-world decision-making processes, and rigorous verification mechanisms:

• At the level of professional data，epiXora™ Covering 56 million pieces of literature metadata and 9.4 million full-text articles, and integrating multi-source professional databases such as clinical trials, regulatory documents, market sales data, and 160 million patent records, comprehensively breaking down the barriers of massive heterogeneous data for subsequentprovide a solid evidentiary foundation for scientific, multi-dimensional assessment.

• On the logical level，epiXora™ incorporates an industry-compliant research framework and decision-making logic, automatically organizing research content around scientific mechanisms, disease associations, clinical progress, competitive landscape, patent risks, and commercialization potential. Users can access “Fast Mode” Obtain a structured brief within 5 minutes to establish an initial assessment; or enter “Deep Mode”, generating a comprehensive report covering multiple dimensions in approximately 30 minutes, significantly reducing secondary processing costs and aligning the research process more closely with real-world decision-making.

• At the level of reliability，epiXora™ is built on the foundation of “trust.” Supported by key assertionsSentence-level Provenance, one-click traceability to the original literature paragraphs. Meanwhile, addressing the common “hallucination” issue of large models in professional applications, epiXora™’sHallucination Detection Feature,It can assist researchers in rapidly reviewing high-risk content with inconsistent identification evidence or missing sources. Research materials and conclusions can be stored in a structured format.Knowledge Map, enabling reuse in subsequent projects and transforming research from one-off outputs into continuously accumulated knowledge assets.

epiXora™ has undergone comprehensive iteration based on user feedback from its predecessor, X-Buddy.Now open for trial use by professionals in the life sciences and pharmaceutical R&D sectors., providing scalable and replicable intelligent solutions for professional research processes that have long relied on manual labor, while also building a more robust foundation for front-end assessment within XtalPi’s “AI + Robotics + Multi-Agent” R&D system. Within this framework, specialized scientific agents are empowering key stages—from target analysis and molecule generation to automated synthesis experiments—through rigorous logic and autonomous reasoning capabilities, driving AI’s evolution from an “efficiency-enhancing auxiliary tool” into a “professional research partner” capable of multi-step collaboration.

From answering a single professional scientific inquiry to building a continuously evolving, highly trustworthy intelligent network, epiXora™ is redefining the efficiency and certainty of professional research with its AI agent capabilities tailored for life sciences. In the future, XtalPi’s dedicated Multi-Agent system will continue to drive deep AI empowerment across core scientific research scenarios, making intelligence-driven scientific discovery the new baseline for industry evolution.

Welcome to clickRead the original textRegister for a TrialepiXora™，Experience the All-New Upgraded Survey!